{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-05T14:07:55.578270+00:00","company":{"ticker":"PRME","cik":1894562,"company_name":"Prime Medicine, Inc."},"pagination":{"limit":100,"returned":6,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"39f4c15f7bc468f238d8934dabb8b2868f921d8c","cik":1894562,"ticker":"PRME","company_name":"Prime Medicine, Inc.","filed_at":"2026-05-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss was $49.1 million for the three months ended March 31, 2026","period_text":"the quarter ended March 31, 2026","report_date":"2026-05-07","result_type":"reported_results","revenue_text":null},"claim":"Prime Medicine, Inc. reported the quarter ended March 31, 2026 results: net income Net loss was $49.1 million for the three months ended March 31, 2026.","evidence_excerpt":"Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the quarter ended March 31, 2026 and provided a business update.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-26-031719","anchor_url":"https://secwatch.observer/filing/0001628280-26-031719#claim-39f4c15f7bc468f238d8934dabb8b2868f921d8c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1894562/000162828026031719/0001628280-26-031719-index.htm"},{"fact_type":"executive_change","fact_key":"2eca06f1a1","cik":1894562,"ticker":"PRME","company_name":"Prime Medicine, Inc.","filed_at":"2025-05-19T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-05-19","interim":false,"role":"member of the Board of Directors","role_category":"director","successor_name":null,"successor_named":false},"claim":"Allan Reine was appointed as member of the Board of Directors at Prime Medicine, Inc..","evidence_excerpt":"The Board also appointed Dr. Reine to serve as a member of the Board as a Class II director","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-122156","anchor_url":"https://secwatch.observer/filing/0001193125-25-122156#claim-2eca06f1a1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1894562/000119312525122156/0001193125-25-122156-index.htm"},{"fact_type":"executive_change","fact_key":"8114b9edde","cik":1894562,"ticker":"PRME","company_name":"Prime Medicine, Inc.","filed_at":"2025-05-19T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-05-19","interim":false,"role":"Chief Executive Officer and principal executive officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Allan Reine was appointed as Chief Executive Officer and principal executive officer at Prime Medicine, Inc..","evidence_excerpt":"the Board appointed Allan Reine, M.D., the Company’s Chief Financial Officer and principal financial officer, as Chief Executive Officer and principal executive officer of the Company","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-122156","anchor_url":"https://secwatch.observer/filing/0001193125-25-122156#claim-8114b9edde","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1894562/000119312525122156/0001193125-25-122156-index.htm"},{"fact_type":"executive_change","fact_key":"70a844909c","cik":1894562,"ticker":"PRME","company_name":"Prime Medicine, Inc.","filed_at":"2025-05-19T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-05-18","interim":false,"role":"President, Chief Executive Officer and principal executive officer","role_category":"ceo","successor_name":"Allan Reine","successor_named":true},"claim":"Keith Gottesdiener resigned as President, Chief Executive Officer and principal executive officer at Prime Medicine, Inc..","evidence_excerpt":"Keith Gottesdiener, M.D. had resigned as President, Chief Executive Officer and principal executive officer of the Company, and as a member of the Board of Directors of the Company","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-122156","anchor_url":"https://secwatch.observer/filing/0001193125-25-122156#claim-70a844909c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1894562/000119312525122156/0001193125-25-122156-index.htm"},{"fact_type":"earnings_release","fact_key":"b9bc6b5a1ab176b3215b67116d83a71be7236fc7","cik":1894562,"ticker":"PRME","company_name":"Prime Medicine, Inc.","filed_at":"2024-05-10T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"first quarter ended March 31, 2024","report_date":"2024-05-10","result_type":"reported_results","revenue_text":null},"claim":"Prime Medicine, Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"today reported financial results for the first quarter ended March 31, 2024","confidence":0.7,"filing_url":"https://secwatch.observer/filing/0001628280-24-022466","anchor_url":"https://secwatch.observer/filing/0001628280-24-022466#claim-b9bc6b5a1ab176b3215b67116d83a71be7236fc7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1894562/000162828024022466/0001628280-24-022466-index.htm"},{"fact_type":"earnings_release","fact_key":"6e5aede81c88e0aca65f83c60357d7c7efc7d45d","cik":1894562,"ticker":"PRME","company_name":"Prime Medicine, Inc.","filed_at":"2024-03-01T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$198.1 million","period_text":"the full year ended December 31, 2023","report_date":"2024-03-01","result_type":"reported_results","revenue_text":null},"claim":"Prime Medicine, Inc. reported the full year ended December 31, 2023 results: net income $198.1 million.","evidence_excerpt":"Net loss was $198.1 million for the year ended December 31, 2023","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-24-008113","anchor_url":"https://secwatch.observer/filing/0001628280-24-008113#claim-6e5aede81c88e0aca65f83c60357d7c7efc7d45d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1894562/000162828024008113/0001628280-24-008113-index.htm"}]}